Encontrados 10 documentos, a visualizar página 1 de 1
Genetic Diversity and Antiretroviral Resistance in HIV-1-Infected Patients Newl...
Leal, Silvânia da Veiga; Pimentel, Victor; Gonçalves, Paloma; Monteiro de Pina Araújo, Isabel Inês; Parreira, Ricardo; Taveira, Nuno; Pingarilho, MartaFunding Information: We thank all clinical and technical support and support received from the Cape Verdean professionals who made this study possible. We deeply thank all the doctors, nurses, laboratory technicians, and healthcare professionals who played a crucial role in collecting and providing the data for this study: Maria Ros\u00E1rio, Elsa Almeida, Idelmira Horta, Kr\u00EDsia Delgado, Suzete Costa, Rise...
An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralisin...
Taveira, Nuno; Figueiredo, Inês; Calado, Rita; Martin, Francisco; Bártolo, Inês; Marcelino, José M.; Borrego, Pedro; Cardoso, Fernando; Barroso, HelenaFunding Information: This work was funded by national funds through the FCT-Foundation for Science and Technology, I.P., under the project UIDB/04585/2020, by FCT and Aga Khan Development Network (AKDN)—Portugal Collaborative Research Network in Portuguese speaking countries in Africa, project 332821690 and by Ministry of Health, Portugal, project HIV/SAU/0008.11. Publisher Copyright: © 2023 by the authors.; Th...
High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lact...
Bártolo, Inês; Moranguinho, Inês; Gonçalves, Paloma; Diniz, Ana Rita; Borrego, Pedro; Martin, Francisco; Figueiredo, Inês; Gomes, PerpétuaFunding Information: This work was supported by Fundação para a Ciência e Tecnologia (FCT), Portugal, Aga Khan Development Network (AKDN)–Portugal Collaborative Research Network in Portuguese-speaking countries in Africa (project 332821690). CQC is supported by FCT through projects UIDB/00313/2020 and UIDP/QUI/00313/2020, co-funded by COMPETE2020-UE. iMed.ULisboa, Faculdade de Farmácia da Universidade de Lisboa...
Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodoma...
Marcelino, Rute; Gramacho, Filipa; Martin, Francisco; Brogueira, Pedro; Janeiro, Nuno; Afonso, Claudia; Badura, Robert; Valadas, Emília; Mansinho, KamalThe ectodomain of gp41 is the target of potent binding and neutralizing antibodies (NAbs) and is being explored in new strategies for antibody-based HIV vaccines. Previous studies have suggested that the W164A-3S (3S) and EC26-2A4 (EC26) peptides located in the gp41 ectodomain may be potential HIV vaccine candidates. We assessed 3S- and EC26-specific binding antibody responses and related neutralizing activity ...
CPLP-TB:
Perdigão, João; Silva, Carla; Diniz, Jaciara; Pereira, Catarina; Machado, Diana; Ramos, Jorge; Silva, Hugo; Abilleira , Fernanda; Brum, ClariceA Tuberculose (TB) permanece um grave problema de saúde pública na Comunidade dos Países de Língua Portuguesa (CPLP). Apesar da ampla variância da incidência da TB nos seus estados-membro e de um fluxo migratório contínuo entre os países que integram este grupo, existe uma enorme lacuna no que diz respeito ao conhecimento da estrutura populacional conjunta do Mycobacterium tuberculosis e circulação de estirpes ...
Epidemic history of hepatitis C virus genotypes and subtypes in Portugal
C., Palladino,; Ifeanyi Jude, Ezeonwumelu,; Marcelino, Rute; Verónica, Briz,; Inês, Moranguinho,; Fátima L., Serejo,; José Fernando, Velosa,Any successful strategy to prevent and control HCV infection requires an understanding of the epidemic behaviour among the different genotypes. Here, we performed the first characterization of the epidemic history and transmission dynamics of HCV subtypes in Portugal. Direct sequencing of NS5B was performed on 230 direct-acting antiviral drugs (DAA)-treatment naïve patients in Lisbon. Phylogenetic analysis was ...
Donor-Recipient Identification in Para- and Poly-phyletic Trees Under Alternati...
Romero-Severson, Ethan O; Bulla, Ingo; Hengartner, Nick; Bártolo, Inês; Abecasis, Ana; Azevedo-Pereira, José M; Taveira, Nuno; Leitner, ThomasCopyright © 2017, Genetics.; Diversity of the founding population of Human Immunodeficiency Virus Type 1 (HIV-1) transmissions raises many important biological, clinical, and epidemiological issues. In up to 40% of sexual infections there is clear evidence for multiple founding variants, which can influence the efficacy of putative prevention methods and the reconstruction of epidemiologic histories. To infer w...
Genetic diversity, transmission dynamics and drug resistance of Mycobacterium t...
Perdigão, João; Clemente, Sofia; Ramos, Jorge; Masakidi, Pedro; Machado, Diana; Silva, Carla; Couto, Isabel; Viveiros, Miguel; Taveira, NunoThe authors wish to thank the laboratory, clinical, and nursing staff of HDP, whose high quality of service and cooperation have made this study possible. Financial support was provided by the Fundacao para a Ciencia e a Tecnologia (FCT) Portugal [PTDC/SAU-EPI/122400/2010], part of the EDCTP2 program supported by the European Union. JP was supported by a post doc fellowship from project [PTDC/SAU-EPI/122400/201...
Evolution of the human immunodeficiency virus type 2 envelope in the first year...
Rocha, Cheila; Calado, Rita; Borrego, Pedro; Marcelino, José M.; Bártolo, Inês; Rosado, Lino; Cavaco-Silva, Patrícia; Gomes, Perpétua; Família, CarlosBackground: Differently from HIV-1, HIV-2 disease progression usually takes decades without antiretroviral therapy and the majority of HIV-2 infected individuals survive as elite controllers with normal CD4+ T cell counts and low or undetectable plasma viral load. Neutralizing antibodies (Nabs) are thought to play a central role in HIV-2 evolution and pathogenesis. However, the dynamic of the Nab response and r...
Baseline susceptibility of primary HIV-2 to entry inhibitors
Borrego, Pedro; Calado, Rita; Marcelino, José M.; Bártolo, Inês; Rocha, Cheila; Cavaco-Silva, Patrícia; Doroana, Manuela; Antunes, FranciscoBackground: The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown. Methods: The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and T-1249, and to the coreceptor antagonists AMD3100, TAK-779 and MVC, was measured using a TZM-bl cell-based assay. ...